# A03-013 Traceability Report

## Purpose

Record the integrity of the administrative source binding created in A03-013.

## Inputs

- `KnowledgeBase/SSRIs/Registries/DRUG_PORTFOLIO_EDITORIAL_REGISTRY.json`
- `ScientificCorpus/Metadata/NORMALIZED_SOURCE_REGISTRY.json`
- `ScientificCorpus/Publication/PUBLICATION_MANIFEST.json`

## Outputs

- `KnowledgeBase/SSRIs/Traceability/DRUG_SOURCE_BINDING.json`
- `KnowledgeBase/SSRIs/Traceability/DRUG_SOURCE_BINDING_INDEX.json`
- `KnowledgeBase/SSRIs/Traceability/SOURCE_BINDING_REGISTRY.json`
- `KnowledgeBase/SSRIs/Traceability/SOURCE_BINDING_MANIFEST.json`
- `KnowledgeBase/SSRIs/Traceability/TRACEABILITY_STATUS.json`

## Checks

| Check | Result |
| --- | --- |
| All Drug IDs have binding | pass |
| All Editorial IDs exist | pass |
| All Source IDs exist | pass |
| Orphan bindings | 0 |
| Missing sources | 0 |
| Drugs without source | 0 |
| Duplicate drugs | 0 |
| Duplicate binding IDs | 0 |
| Scientific content created | no |
| Source content interpreted | no |

## Source Count

17 source IDs are referenced by the core binding layer.

## Drug Count

6 core SSRI drug IDs are bound.

## Binding Count

6 core bindings are present.

## Boundary Candidate Status

Vilazodone and vortioxetine remain tracked as boundary candidates only:

- `review_required`;
- `not_included`;
- `ontology_decision: not_decided`.

## Prohibited Use

The traceability layer cannot be used for:

- evidence grading;
- clinical field population;
- Drug Profile population;
- Safety Profile population;
- therapeutic recommendation;
- prescription;
- runtime inference.

## Declaration Final

The A03-013 traceability layer is structurally valid and metadata-only. It preserves source traceability without converting any source into clinical knowledge.
